Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regeneron ...

Regeneron acquires rights to HS-20094, a promising obesity treatment from Hansoh Pharma, enhancing its metabolic programs. Quiver AI Summary. Regeneron Pharmaceuticals has entered a strategic ...

Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Big Pharma targets pain, obesity, and neuroscience in 2025 deal spree Eli Lilly, Regeneron, and Biogen lead a surge in strategic acquisitions and partnerships focused on high-demand therapeutic areas ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with annual revenue of $14.1 billion and strong financial health according to InvestingPro ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will ...